Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort-Reference-Cited by-同舟云学术

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort

Published:2009-03-31 Issue:6 Volume:63 Page:1251-1255
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:Journal of Antimicrobial Chemotherapy

Author:

Wittkop L.,Breilh D.,Da Silva D.,Duffau P.,Mercie P.,Raymond I.,Anies G.,Fleury H.,Saux M.-C.,Dabis F.,Fagard C.,Thiebaut R.,Masquelier B.,Pellegrin I.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/63/6/1251/2246889/dkp114.pdf

Reference9 articles.

1. Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection

2. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

3. Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

4. A Conventional LC-MS Method Developed for the Determination of Plasma Raltegravir Concentrations

5. Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12

2. Spectrometric and computational studies of the binding of HIV-1 integrase inhibitors to viral DNA extremities;PeerJ Physical Chemistry;2019-12-02

3. Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting;AIDS;2019-06-01

4. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens;HIV Medicine;2017-10-06

5. The inhibition process of HIV-1 integrase by diketoacids molecules: Understanding the factors governing the better efficiency of dolutegravir;Biochemical and Biophysical Research Communications;2017-07